How many drugs treat Peripheral T-cell lymphoma?

Drug Landscape tracks 9 marketed treatments for Peripheral T-cell lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/peripheral-t-cell-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peripheral T-cell lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peripheral T-cell lymphoma (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peripheral T-cell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Poteligeo	MOGAMULIZUMAB	Kyowa Kirin	Chemokine Receptor Type 4 Interaction [EPC]	C-C chemokine receptor type 4	2018-01-01
Immucillin H	FORODESINE	Mundi Pharma		Purine nucleoside phosphorylase	2017-01-01
Beleodaq	belinostat	Acrotech Biopharma	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 1	2014-01-01
Istodax	ROMIDEPSIN	Teva Pharms Usa Inc	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Poteligeo	Poteligeo	Kyowa Kirin Pharmaceutical Development Ltd		C-C chemokine receptor type 4
Istodax	Istodax	Celgene		Bromodomain-containing protein 4, Histone deacetylase 3/NCoR1, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)
Chidamide	Chidamide	Sun Yat-sen University		Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10
Folotyn	Folotyn	Acrotech Biopharma Inc.		Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase
Mogamulizumab-Kpkc	Mogamulizumab-Kpkc	H. Lee Moffitt Cancer Center and Research Institute	Chemokine Receptor Type 4 Interaction [EPC]	C-C chemokine receptor type 4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Acrotech Biopharma · 1 drug in Peripheral T-cell lymphoma
Acrotech Biopharma Inc. · 1 drug in Peripheral T-cell lymphoma
Celgene · 1 drug in Peripheral T-cell lymphoma
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in Peripheral T-cell lymphoma
Kyowa Kirin · 1 drug in Peripheral T-cell lymphoma
Kyowa Kirin Pharmaceutical Development Ltd · 1 drug in Peripheral T-cell lymphoma
Mundi Pharma · 1 drug in Peripheral T-cell lymphoma
Sun Yat-sen University · 1 drug in Peripheral T-cell lymphoma
Teva Pharms Usa Inc · 1 drug in Peripheral T-cell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peripheral T-cell lymphoma:

Cite this brief

Drug Landscape (2026). Peripheral T-cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-t-cell-lymphoma. Accessed 2026-06-10.

Peripheral T-cell lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing